Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.

Images from 2D TIRF-SIM-TFM and aTFM microscopic methodologies.
Images from 2D TIRF-SIM-TFM and aTFM microscopic methodologies.

Two recent publications from the Biophysical Immunology Lab, led by Prof Fritzsche at the Rosalind Franklin Institute and Kennedy Institute of Rheumatology at the University of Oxford, have established novel methodologies to measure the small forces occurring in immune cells during an immune response.

The work, led by Dr. Huw Colin-York and Liliana Barbieri in Prof Marco Fritzsche's group, develops and applies new force probing methodologies by combining traction force microscopy and the unique TIRF-SIM technology established between the Fritzsche and Dustin groups in close collaboration with Prof Dong Li (Institute of Biophysics at the Chinese Academy of Science) and Prof Eric Betzig (HHMI Janelia, Noble Laureate in chemistry 2014) at the Kennedy. 

Quantifying small, rapidly evolving forces generated by cells of the immune system is a major challenge for the understanding of biomechanics and mechanobiology in health and disease. The establishment of the two force probing methods allows for measurement of small forces on the pico-Newton range at unprecedented sensitivity in 2D and 3D.

Prof Fritzsche says: "These methods offers a combination of spatio-temporal resolution enhancement relevant to forces on the nano- and sub-second scales, opening up new aspects of mechanobiology of the immune response to analysis."

The study was carried out in close collaboration with Prof Dustin at the Kennedy Institute and Prof Emad Moendarbary's group at UCL and was published in two papers in Nature Communications earlier this month.

 

Li D*, Colin-York H*, Barbieri L*, Javanmardi Y, Guo T, Korobchevskaya K, Moendarbary E, Li D, Fritzsche M, Astigmatic Traction force microscopy (aTFM)Nature Communications, 2021 (*co-first authors). 

 

Barbieri L*, Colin-York H*, Korobchevskaya K*, Li D, Karedla N, Schneider F, Dustin M, Li D, Fritzsche M, Two-dimensional TIRF-SIM Traction Force Microscopy (2D TIRF-SIM-TFM)Nature Communications, 2021 (*co-first authors). 

 

Korobchevskaya K, Colin-York H, Barbieri L, Fritzsche M, Extended mechanical force measurements using structured illumination microscopyPhilosophical Transactions Royal Society A, 2021. 

Find out more about the microscope technology

Similar stories

Communication at the crossroads of the immune system

In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

New research suggests targeting blood vessels could be key to controlling fibrotic disease

By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.